Clinical Trials Logo

Advanced Malignant Neoplasm clinical trials

View clinical trials related to Advanced Malignant Neoplasm.

Filter by:

NCT ID: NCT06394713 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Start date: June 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.

NCT ID: NCT06344351 Recruiting - Clinical trials for Advanced Malignant Neoplasm

A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

Start date: April 25, 2024
Phase: Phase 1
Study type: Interventional

This study includes two stage: dose escalation and dose extension, with a single dose and a multiple dose study. This is a single-center, open, non-randomized, single arm, study to evaluate the safety, tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer.

NCT ID: NCT06297642 Recruiting - Clinical trials for Advanced Malignant Neoplasm

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.

NCT ID: NCT06165822 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

Start date: December 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.

NCT ID: NCT06165809 Withdrawn - Clinical trials for Advanced Malignant Neoplasm

A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer

Start date: December 2023
Phase: Phase 1
Study type: Interventional

This study is divided into two stages: dose escalation and dose extension, including a single dose and a multiple dose clinical study. This is a single-center, open, non randomized, single arm study to the safety and tolerability of TQB3015 tables in patients with advanced malignant cancer.

NCT ID: NCT05997342 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor

Start date: August 2023
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AEs) and serious adverse events (SAEs), pharmacokinetic parameters and antitumor effect of TQB3912 tablets in Chinese adult patients with advanced malignant neoplasm. The study was divided into phase Ia and phase Ib, Phase Ia: Dose escalation period, to evaluate the safety and tolerability of TQB3912 tablets, determine MTD; Phase Ib: Effectiveness exploration period, to expand the safe and effective dose group, and to recommend appropriate dosage and method for subsequent clinical research.

NCT ID: NCT05985278 Recruiting - Clinical trials for Advanced Malignant Neoplasm

Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy

Start date: July 6, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the retention in tumour and distribution behavior of [Lu-177]-Catalase after intratumoral injection,and preliminary evaluation the efficacy and safety of [Lu-177]-Catalase.

NCT ID: NCT05867563 Recruiting - Clinical trials for Advanced Malignant Neoplasm

Clinical Trial Evaluating the Safety of the TQB2103 for Injection

Start date: July 4, 2023
Phase: Phase 1
Study type: Interventional

TQB2103 injection is an antibody-drug conjugate (ADC) targeting claudin (CLDN) 18.2. This study aimed to evaluate the safety and tolerability, pharmacokinetic characteristics and immunogenicity of TQB2103 injection in patients with advanced malignant tumors as well as its initial effectiveness.

NCT ID: NCT05861947 Recruiting - Gastric Cancer Clinical Trials

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

JIVAN
Start date: August 26, 2023
Phase: Phase 1
Study type: Interventional

A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed Advanced Malignancies (JIVAN).

NCT ID: NCT05048160 Recruiting - Clinical trials for Advanced Malignant Neoplasm

A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

Start date: September 27, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single arm, non-randomized, open label, multiple doses phase I/II international, multicenter clinical trial to evaluate safety, tolerability, PK/PD, immunogenicity and preliminary efficacy in subjects with advanced malignant neoplasm. The study is consisted of two stages: dose escalation and clinical expansion. Only Phase I has been submitted to US FDA,and the protocol number is still the same as 6MW3211-2021-CP101.The US title is : A Phase 1, First-in-Human (FIH), Multicenter, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 6MW3211 in Patients with Advanced Malignancies .